We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-2.48%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.43B
AUM Growth
+$280M
(+13%)
Cap. Flow
-$9.04M
Cap. Flow
% of AUM
-0.37%
Top 10 Holdings %
Top 10 Hldgs %
37.47%
Holding
114
New
20
Increased
14
Reduced
20
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$49M |
| 2 |
LCI
Lannett Company, Inc.
LCI
|
+$46.3M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$45.7M |
| 4 |
Elevance Health
ELV
|
+$42.6M |
| 5 |
Centene
CNC
|
+$35.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DaVita
DVA
|
+$23.1M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$19.2M |
| 3 |
SEM
Select Medical
SEM
|
+$18.3M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$16.4M |
| 5 |
AET
Aetna Inc
AET
|
+$14.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.33% |
| 2 | Financials | 2.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SYRS
26
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $22M | 0.91% |
181,278
| – | – |
|
27
Ascendis Pharma A/S
ASND
$16.5B
| $21.3M | 0.87% |
+1,050,000
| New | +$21M |
|
28
BioCryst Pharmaceuticals
BCRX
$2.32B
| $20.5M | 0.84% |
3,237,734
-1,164,112
| -26% | -$6.06M |
|
|
MNK
29
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $20.3M | 0.83% |
+407,000
| New | +$24M |
|
|
EPZM
30
DELISTED
Epizyme, Inc
EPZM
| $19.4M | 0.8% |
1,601,049
+1,309,870
| +450% | +$13.7M |
|
|
BLUE
31
DELISTED
bluebird bio
BLUE
| $18.6M | 0.77% |
23,316
+6,023
| +35% | +$4.78M |
|
|
MYOV
32
DELISTED
Myovant Sciences Ltd.
MYOV
| $18.6M | 0.77% |
+1,496,675
| New | +$17.3M |
|
33
CALL
Viatris
VTRS
$19.8B
| $17.2M | 0.71% |
+450,000
| New | +$16.7M |
|
|
SCTL
34
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $16.7M | 0.69% |
+2,313,625
| New | +$15.8M |
|
35
Axogen
AXGN
$2.1B
| $16.5M | 0.68% |
1,838,225
-54,805
| -3% | -$472K |
|
36
Zimmer Biomet
ZBH
$17.4B
| $15.5M | 0.64% |
+154,500
| New | +$16.6M |
|
|
TSRO
37
DELISTED
TESARO, Inc.
TSRO
| $15.1M | 0.62% |
112,200
-130,100
| -54% | -$16.4M |
|
38
Cartesian Therapeutics
RNAC
$240M
| $14.6M | 0.6% |
+28,440
| New | +$16.6M |
|
|
ARRY
39
DELISTED
Array Biopharma Inc
ARRY
| $14.5M | 0.6% |
1,650,000
| – | – |
|
|
AAC
40
DELISTED
AAC Holdings
AAC
| $14.3M | 0.59% |
1,975,347
-214,502
| -10% | -$2.45M |
|
|
ONCE
41
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $14.1M | 0.58% |
283,000
-85,000
| -23% | -$4.55M |
|
|
FOMX
42
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $13.7M | 0.56% |
1,232,844
-74,214
| -6% | -$698K |
|
43
Glaukos
GKOS
$9.13B
| $13.5M | 0.56% |
393,228
-110,049
| -22% | -$3.77M |
|
|
KITE
44
DELISTED
Kite Pharma, Inc.
KITE
| $13.4M | 0.55% |
+297,902
| New | +$14.6M |
|
45
Wave Life Sciences
WVE
$1.1B
| $12.3M | 0.51% |
+472,124
| New | +$15.4M |
|
|
ADPT
46
DELISTED
Adeptus Health Inc
ADPT
| $12.2M | 0.5% |
1,600,861
| – | – |
|
47
CytomX Therapeutics
CTMX
$766M
| $10.4M | 0.43% |
943,433
| – | – |
|
48
Ionis Pharmaceuticals
IONS
$8.75B
| $10.2M | 0.42% |
+214,095
| New | +$8.47M |
|
49
Aclaris Therapeutics
ACRS
$778M
| $10.2M | 0.42% |
375,000
+259,000
| +223% | +$6.6M |
|
|
IVTY
50
DELISTED
Invuity, Inc
IVTY
| $9.72M | 0.4% |
1,690,498
+407,900
| +32% | +$3.41M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q4 2016 Portfolio in Review
As of Q4 2016, Deerfield Management held 114 positions worth $2.43B, up 13% from $2.15B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Deerfield Management's Q4 2016 filing shows 20 new, 14 increased, 20 reduced and 12 closed positions. Its largest new stake was Lannett Company, Inc.: 501,888 shares worth $44.3M. The largest sale was DaVita, an estimated $23.1M.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 70% a quarter earlier, followed by Financials.
- Deerfield Management's largest Q4 2016 buy was Lannett Company, Inc.: 501,888 shares worth $44.3M.
- Deerfield Management added most to Blueprint Medicines in Q4 2016, an estimated $49M increase.
- Deerfield Management's biggest Q4 2016 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $19.2M.
- Deerfield Management fully exited DaVita in Q4 2016, selling an estimated $23.1M.
- Deerfield Management's ten largest holdings make up 37% of its $2.43B portfolio in Q4 2016.
- Deerfield Management opened 20 new positions and closed 12 in Q4 2016.
- Deerfield Management's portfolio value rose 13% quarter-over-quarter to $2.43B.
Based on Deerfield Management's 13F filing for Q4 2016, filed 14 Feb 2017.